Buying Lexaria is a no-brainer at this point (CSE: LXX)
Lexaria Bioscience Corp. (CSE:LXX, OTCQX:LXRP) reports it has proven in animal testing that their DehydraTECH™ technology delivers cannabinoids to the bloodstream far more quickly and effectively than conventional industry cannabinoid edible formulation designs that often combine cannabinoids with MCT oils such as coconut oil. The finds from a recent test included the following findings:
The DehydraTECH formulation delivered measurable quantities of cannabidiol (CBD) into blood in as little as 2 minutes;
LXRP’s technology delivered more CBD to bloodstream in 15 minutes than conventional medium chain triglyceride (“MCT”) oil based control formulation achieved in 60 minutes;
The area under the curve (“AUC”) for LXRP’s patented DehydraTECH formulation was 389% more than the MCT oil control formulation;
LXRP’s DehydraTECH formulation delivers cannabinoids at industry-leading volumes and speed while effectively masking bitter flavor and aroma profiles.
One reason I continue to like LXRP from an investment perspective is the company continues to build its base of scientific knowledge and Intellectual Property even as the all-important testing with Altria (NYSE: MO) goes on “in camera.” In addition, the current correction in cannabis stock prices has treated LXRP harshly with the stock recently trading below a dollar. At this price, buying LXRP is a no-brainer.